ARS Pharmaceuticals, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.7M | $22.7M | $28.1M | $32.5M | $15.7M | $8.0M | $86.6M | $2.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $4.7M | $4.3M | $3.4M | $2.8M | $4.0M | $3.0M | $3.0M | $4.4M |
| SG&A Expense | $77.6M | $72.2M | $60.0M | $74.8M | $54.3M | $41.1M | $35.5M | $19.3M |
| Operating Income | $-61.5M | $-60.1M | $-41.5M | $-53.2M | $-47.6M | $-37.2M | $47.2M | $-21.7M |
| Operating Margin | -182.6% | -265.2% | -147.6% | -163.7% | -302.9% | -466.3% | 54.5% | -1,051.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-62.3M | $-60.6M | $-41.3M | $-51.2M | $-44.9M | $-33.9M | $49.9M | $-19.1M |
| Net Margin | -185.2% | -267.3% | -147.1% | -157.4% | -285.6% | -425.7% | 57.7% | -925.0% |
| EPS (Basic) | $-0.63 | $-0.61 | $-0.41 | $-0.52 | $-0.46 | $-0.35 | $0.52 | $-0.20 |
| EPS (Diluted) | $-0.63 | $-0.61 | $-0.41 | $-0.52 | $-0.46 | $-0.35 | $0.52 | $-0.20 |
| Shares Outstanding (Basic) | 99.3M | 99.3M | 98.6M | 98.8M | 98.4M | 98.1M | 96.9M | 97.0M |
| Shares Outstanding (Diluted) | 99.3M | 99.3M | 98.6M | 98.8M | 98.4M | 98.1M | 102.4M | 97.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |